

Joint Committee on Vaccination and Immunisation

Advice on influenza vaccines for 2021/22

November 2020

You may re-use the text of this document (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit www.nationalarchives.gov.uk/doc/open-government-licence/

© Crown copyright 2020

Published to gov.uk, in PDF format only.

www.gov.uk/dh

Joint Committee on Vaccination and Immunisation

Advice on influenza vaccines for 2021/22

Prepared by the Joint Committee on Vaccination and Immunisation scientific secretariat

Contents

Contents	4
JCVI advice on influenza vaccines for the 2021/2022 influenza season	5-7
Background.....	7
Glossary	8
Selected references	9

JCVI advice on influenza vaccines for the 2021/2022 influenza season

JCVI has reviewed the latest evidence on influenza vaccines. The advice below represents the JCVI's scientific view on the use of influenza vaccines in the UK for the 2021/2022 influenza season. This includes vaccines anticipated for licensure before or during the ordering window for the 2021/22 influenza season. Vaccines should normally only be considered for use in the relevant populations once licensed. Changes to the vaccine portfolio available for 2021/22 include the replacement of trivalent for quadrivalent formulations for the adjuvanted and high dose influenza vaccines and the expected licensure of a recombinant quadrivalent vaccine in November 2020. The cell based quadrivalent vaccine is now licensed from the age of two years and above.

The advice below represents the JCVI's scientific view on the use of influenza vaccines in the UK for the 2021/22 influenza season.

Adults 65 years of age and over

For vaccination of those aged 65 years and over JCVI advises the use of the following vaccines:

- Adjuvanted quadrivalent inactivated influenza vaccine (aQIV)
- High-dose quadrivalent inactivated influenza vaccine (QIV-HD)

Considerations

The available evidence indicates additional benefit from the use of aQIV or QIV-HD in those aged 65 years and over, compared with standard dose egg-culture inactivated trivalent and quadrivalent vaccines (TIVe/QIVe).

When considering a preference between QIV-HD and aQIV, the available data comparing these are few, somewhat inconsistent, are not available over multiple seasons, are at risk of bias, and are limited by the use of non-laboratory confirmed influenza endpoints. The level of uncertainty in the available evidence is considered too great to allow for a preferential recommendation between the vaccines.

If aQIV or QIV-HD are not available, the quadrivalent influenza cell-culture vaccine (QIVc) and the Quadrivalent Recombinant Influenza Vaccine (QIVr) are considered acceptable alternatives and are suitable for use in this age group. QIVc and QIVr are considered preferable to standard egg-culture influenza vaccines (TIVe/QIVe) in this age group, for reasons outlined below.

Further comparative data are required, preferably from the same country over multiple seasons and with laboratory confirmed influenza endpoints, to support consideration of the relative effectiveness of aQIV, compared with QIV-HD and for QIVc and QIVr.

At-risk adults (including pregnant women) aged less than 65 years of age

For vaccination of adults aged 18 to less than 65 years of age in an at-risk group JCVI advises the use of the influenza vaccines below:

- Quadrivalent influenza cell-culture vaccine (QIVc)
- Quadrivalent Recombinant Influenza Vaccine (QIVr)

The Quadrivalent influenza egg-culture vaccine (QIVe) can also be considered for use in this age group if other options are not available subject to the considerations below.

Considerations

Evidence from recent influenza seasons indicate a clear additional benefit in the use of quadrivalent influenza vaccines in those less than 65 years of age in an at-risk group, compared with trivalent influenza vaccines.

There is a potential advantage to using influenza vaccines which do not use egg in the manufacturing process (cell-culture or recombinant) compared with egg-cultured influenza vaccines, due to the possible impact of “egg-adaption” on the effectiveness of influenza vaccines, particularly against A(H3N2) strains. The evidence on additional benefit is available for only very few seasons but the issue of egg adaptation remains a real concern particularly for the AH3N2 virus which is the more virulent influenza subtype in terms of morbidity and mortality.

There is limited but good evidence that the recombinant vaccine QIVr, which also is not affected by egg adaption, is more effective than QIVe in adults under 65 years age. Therefore, QIVr is also preferred over QIVe in adults under 65 years old. The Committee notes that, QIVc has also been used more extensively than QIVr in the UK and there is more real-world effectiveness data in support of this vaccine.

Of the two non-egg manufactured vaccines the Committee notes that QIVc contains whole inactivated virus while QIVr contains only the haemagglutinin protein and not the neuraminidase subunit protein. JCVI undertook a further review of the available data on neuraminidase, as planned at the meeting on October 27 (minute to be published on 8 December), and noted that while there was some evidence of a role in protection after infection, JCVI did not find strong supporting evidence for the role of neuraminidase in vaccine protection. Whilst there may be a theoretical advantage for an influenza vaccine that contains neuraminidase there is uncertainty about the quantity of neuraminidase or the presence of antigenic epitopes contained in current products. In view of this review, JCVI considers that QIVc and QIVr should be considered acceptable alternatives. The Committee will keep this issue under review and look for more evidence on the role of neuraminidase and its quantification in influenza vaccines.

Based on the available evidence the Committee supports a preference for QIVc and QIVr over QIVe. The quadrivalent egg-culture inactivated vaccine (QIVe) can also be considered for use in this group because any impact of egg adaptation will likely be limited to seasons in which the influenza season is dominated by well- matched H3N2 strains.

Children aged two to less than 18 years of age in an at-risk group

For vaccination of children aged two to less than 18 years of age in an at-risk group, the live attenuated influenza vaccine (LAIV) is the first choice. In those for whom LAIV is not suitable, JCVI advises the use of the influenza vaccines below in the following order of preference:

1. Quadrivalent influenza cell-culture vaccine (QIVc)¹
2. Quadrivalent influenza egg-culture vaccine (QIVe)

Children aged less two years old

For vaccination of at-risk children aged less than 2 years of age in an at-risk group JCVI advises the use of the following vaccine:

- Quadrivalent influenza egg-culture vaccine (QIVe)²

Operational considerations

The Committee is mindful that other factors than purely scientific and clinical advice need to be considered from an operational perspective, which include availability of supply and affordability, which will contribute to the decisions on which vaccines are purchased for the 2021/22 season. The aim of this advice is to provide a framework from which NHS England and PHE can take forward planning for the delivery of the Influenza programme in 2021/22 and communicate this clearly to providers and the public.

¹ The Quadrivalent influenza cell-culture vaccine (QIVc) is egg free and egg allergic individuals can be safely vaccinated in any setting with this vaccine, including those who have required admission to intensive care for a previous severe anaphylaxis to egg.

² The quadrivalent influenza egg culture vaccine (QIVe) is the only available influenza vaccine licensed for use in children aged less than two years old

Background

The considerations of JCVI with regards to use of these vaccines are published in the minutes of JCVI and the Influenza sub-committee

The advice of JCVI is based on discussions at JCVI and the Influenza sub-committee:

1. adjuvanted influenza vaccines were discussed in the June and October 2017 JCVI meetings, and the September 2019 Influenza sub-committee;
2. high dose influenza vaccines were discussed in the June 2018 JCVI meeting, the September 2018 Influenza sub-committee, and the September 2019 Influenza sub-committee;
3. cell-culture vaccines were discussed in the September 2018 Influenza sub-committee meeting, the October 2018 JCVI meeting, and the September 2019 Influenza sub-committee;
4. advice for the 2021/22 season was discussed via teleconference with the JCVI and invited experts from influenza subcommittee on 27 October 2020. The minutes of this meeting will be published on the 8 December 2020.

The minutes JCVI and sub-committee meetings are available through the JCVI webpage at <https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation>

Glossary

aQIV - Adjuvanted egg-cultured quadrivalent inactivated influenza vaccine

LAIV - Live attenuated egg-cultured intranasal influenza vaccine

QIVc - Cell-cultured quadrivalent inactivated influenza vaccine

QIVe - Egg-cultured quadrivalent inactivated influenza vaccine

QIVr – Recombinant quadrivalent inactivated influenza vaccine

TIVe - Egg-cultured trivalent inactivated influenza vaccine

QIV-HD - High-dose egg-cultured quadrivalent inactivated influenza vaccine

Selected references

- Bella *et al* (2019) Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 - 2018 season. *Expert Rev Vaccines*. 2019 Jun;18(6):671-679.
- Boikos C, Sylvester GC, Sampalis JS, Mansi JA. Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-Derived Quadrivalent Influenza Vaccines in Preventing Influenza-Like Illness in 2017-2018. *Clinical infectious diseases* 2020; Apr 7:ciaa371. doi: 10.1093/cid/ciaa371.
- Bruxvoort KJ, Luo Y, Ackerson B, et al. Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018. *Vaccine* 2019; 37(39): 5807-11.
- European Centre for Disease Prevention and Control. Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory confirmed influenza in individuals aged 18 years and over. Stockholm: ECDC; 2020
- DiazGranados *et al* (2014) Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med*; 371: 635–45.
- Divino *et al* (2019) Real-World outcomes of adjuvanted trivalent Influenza vaccine compared to egg-based trivalent high-dose, egg-based quadrivalent and trivalent vaccines among the U.S. elderly during 2016-2018 Flu seasons using Claims Data. Poster Presented at OPTION X Congress; August 31st 2019, Singapore.
- Divino *et al* (2019) Hospitalization encounters following vaccination with adjuvanted trivalent Influenza vaccine compared to egg-based trivalent high-dose, egg-based quadrivalent and trivalent vaccines among the U.S. elderly using claims data. Poster Presented at OPTION X Congress; August 31st 2019, Singapore.
- Divino V et al. A real-world study evaluating the relative vaccine effectiveness of a cell based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season. *Vaccine* 2020; 38: 6334–6343.
- Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. *New England Journal of Medicine*. 2017;376(25):2427-36.
- Dunkle LM, Izikson R, Patriarca PA, Goldenthal KL, Muse D, Cox MMJ. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age. *J Infect Dis*. 2017 Dec 5;216(10):1219-1226. doi: 10.1093/infdis/jix478. PMID: 28968871.
- Eichelberger MC, Wan H. Influenza neuraminidase as a vaccine antigen. *Curr Top Microbiol Immunol*. 2015;386:275-99. doi: 10.1007/82_2014_398. PMID: 25033754. 6)
- Eick-Cost AA. Relative effectiveness of cell-based influenza vaccines compared with egg-based influenza vaccines, active component U.S. Service members, 2017–18 season International Conference on Emerging Infectious Diseases. Atlanta, GA.; 2018.Gravenstein *et al* (2017) Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. *Lancet Respir Med*. 2017

Sep;5(9):738-746.

Gravenstein *et al* (2018) Feasibility of a cluster-randomized influenza vaccination trial in U.S. nursing homes: Lessons learned. *Hum Vaccin Immunother*. 2018 Mar 4;14(3):736-743

Giurgea LT, Morens DM, Taubenberger JK *et al*. Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine. *Vaccines* 2020;8:409 doi.org/10.3390/vaccines8030409

Izurieta *et al* (2015) Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. *Lancet Infect Dis*. 2015 Mar;15(3):293-300

Izurieta *et al* (2019) Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017–2018. *J Infect Dis*. 2019 Sep 13;220(8):1255- 1264

Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of influenza vaccines among the U.S. elderly, 2018-19. *J Infect Dis* 2020; 222:278–87.

Krammer F, Lei L, Wilson P Emerging from the Shadow of Hemagglutinin: Neuraminidase Is an Important Target for Influenza Vaccination. *Cell Host & Microbe* 2019; 26(6):712-713.
:https://doi.org/10.1016/j.chom.2019.11.006.

Lapi *et al* (2019) Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. *Expert Rev Vaccines*. 2019; 18(6):663-670

Mannino *et al* (2012) Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy. *American Journal of Epidemiology*. 176(6) 527–533

Maryna C Eichelberger, Arnold S Monto, Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection, *The Journal of Infectious Diseases*, Volume 219, Issue Supplement_1, 15 April 2019, Pages S75–S80, https://doi.org/10.1093/infdis/jiz017

Pelton SI, Divino V, Shah D et al. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season. *Vaccines* 2020, 8, 446

Rijal, Pramila & Wang, Bei & Tan, Tiong & Schimanski, Lisa & Janesch, Philipp & Dong, Tao & McCauley, John & Daniels, Rodney & Townsend, Alain & Huang, Kuan-Ying. (2019). Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans. 10.1101/682450. 5)

Robison & Thomas (2018) Assessing the effectiveness of high-dose influenza vaccine in preventing hospitalization among seniors, and observations on the limitations of effectiveness study design. *Vaccine*. 2018 Oct 29;36(45):6683-6687

Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. *Vaccine*. 2011;29(44):7733-9.

van Aalst R, Gravenstein S, Mor V, Mahmud SM, Wilschut J, Postma M, Chit A. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study. *Vaccine*. 2020 Jan 10;38(2):372-379. doi: 10.1016/j.vaccine.2019.09.105. Epub 2019 Oct 9. PMID: 31606249.

Van Buynder *et al* (2013) The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. *Vaccine*. 31(51) 6122-6128

Young-Xu *et al* (2018) Relative Vaccine Effectiveness of High-Dose Versus Standard-Dose Influenza

Vaccines Among Veterans Health Administration Patients. *J Infect Dis.* 217, 11, 1718–1727

Young-Xu *et al* (2019) Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method. *Vaccine* 37(11) 1484-1490